Moderna, Inc. Common Stock vs. Novavax Inc
Novavax Inc (NVAX) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| MRNA | NVAX | |
|---|---|---|
| Market Cap | $59.75 billion | $1.49 billion |
| Revenue (TTM) | $2.23 billion | $413.80 million |
| Net Income (TTM) | $-3,151,000,000 | $-247,730,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MRNA | NVAX | |
|---|---|---|
| Price / Book | 8.84 | -7.83 |
| Price / Sales | 26.82 | 3.61 |
NVAX leads on 2 of 2 valuation factors.
Profitability
| MRNA | NVAX | |
|---|---|---|
| Net Margin | -141.43% | -59.87% |
| Return on Equity | -46.61% | 129.90% |
NVAX leads on 2 of 2 profitability factors.
Dividend
| MRNA | NVAX | |
|---|---|---|
| Dividend Yield | — | 14.09% |
MRNA and NVAX split the dividend factors evenly.
Risk & Sentiment
| MRNA | NVAX | |
|---|---|---|
| Short Interest | 0.01% | 25.98% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, NVAX overview, NVAX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.